Angélica Vega-García , Luisa Rocha, Rosalinda Guevara-Guzmán , Christian Guerra-Araiza , Iris Feria-Romero, Juan M. Gallardo, Teresa Neri-Gomez, José E. Suárez-Santiago and Sandra Orozco-Suarez* Pages 1388 - 1401 ( 14 )
Background: Neuroinflammation induced in response to damage caused by status epilepticus (SE) activates the interleukin (IL)1-β pathway and proinflammatory proteins that increase vulnerability to the development of spontaneous seizure activity and/or epilepsy.
Objectives: The study aimed to assess the short-term anti-inflammatory and neuroprotective effects of Magnolia officinalis (MO) on recurrent SE in immature rats.
Methods: Sprague-Dawley rats at PN day 10 were used; n = 60 rats were divided into two control groups, SHAM and KA, and two experimental groups, MO (KA-MO) and Celecoxib (KA-Clbx). The anti-inflammatory effect of a single dose of MO was evaluated at 6 and 24 hr by Western blotting and on day 30 PN via a subchronic administration of MO to assess neuronal preservation and hippocampal gliosis by immunohistochemistry for NeunN and GFAP, respectively.
Results: KA-MO caused a decrease in the expression of IL1-β and Cox-2 at 6 and 24 h post-treatment, a reduction in iNOS synthase at 6 and 24 hr post-treatment and reduced neuronal loss and gliosis at postnatal day 30, similar to Clbx.
Conclusion: The results indicating that Magnolia officinalis is an alternative preventive treatment for early stages of epileptogenesis are encouraging.
Magnolia officinalis, Kainic acid, Status epilepticus, neuroinflammation, neuroprotection, epileptogenesis
Unidad de Investigacion Medica en Enfermedades Neurologicas, Hospital de Especialidades, “Dr. Bernardo Sepulveda”, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, IMSS, Ciudad de Mexico, Departamento de Farmacobiologia, Centro de Investigacion y Estudios Avanzados, Tlalpan, Ciudad de Mexico, Departamento de Fisiologia, Facultad de Medicina, Universidad Nacional Autonoma de Mexico, Ciudad de Mexico, Unidad de Investigacion Medica en Farmacologia, Hospital de Especialidades, “Dr. Bernardo Sepulveda”, Centro Medico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, IMSS, Ciudad de Mexico, Unidad de Investigacion Medica en Enfermedades Neurologicas, Hospital de Especialidades, “Dr. Bernardo Sepulveda”, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, IMSS, Ciudad de Mexico, Unidad de Investigacion Medica en Enfermedades Nefrologicas, Hospital de Especialidades, “Dr. Bernardo Sepulveda”, Centro Medico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, IMSS, Ciudad de Mexico, Unidad de Investigacion Biomolecular del Hospital de Cardiologia, Centro Medico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico DF, Escuela Superior de Medicina. Instituto Politecnico Nacional. Ciudad de Mexico, Departamento de Fisiologia, Facultad de Medicina, Universidad Nacional Autonoma de Mexico, Ciudad de Mexico